2,239 Shares in Johnson & Johnson (NYSE:JNJ) Purchased by Strategent Financial LLC

Strategent Financial LLC acquired a new position in shares of Johnson & Johnson (NYSE:JNJ) during the 4th quarter, Holdings Channel.com reports. The fund acquired 2,239 shares of the company’s stock, valued at approximately $324,000. Johnson & Johnson comprises approximately 0.3% of Strategent Financial LLC’s holdings, making the stock its 26th largest holding.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Vaughan David Investments LLC IL grew its stake in shares of Johnson & Johnson by 0.8% in the 4th quarter. Vaughan David Investments LLC IL now owns 311,991 shares of the company’s stock worth $45,120,000 after buying an additional 2,554 shares during the last quarter. Exchange Capital Management Inc. boosted its holdings in Johnson & Johnson by 14.0% in the fourth quarter. Exchange Capital Management Inc. now owns 19,693 shares of the company’s stock worth $2,848,000 after acquiring an additional 2,418 shares in the last quarter. Stack Financial Management Inc grew its stake in shares of Johnson & Johnson by 0.5% in the fourth quarter. Stack Financial Management Inc now owns 113,279 shares of the company’s stock worth $16,382,000 after acquiring an additional 516 shares during the last quarter. Pine Valley Investments Ltd Liability Co raised its position in shares of Johnson & Johnson by 18.7% in the 4th quarter. Pine Valley Investments Ltd Liability Co now owns 117,542 shares of the company’s stock worth $16,999,000 after purchasing an additional 18,554 shares during the last quarter. Finally, BankPlus Trust Department bought a new position in Johnson & Johnson in the 4th quarter worth about $392,000. Institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on JNJ shares. Raymond James reduced their price objective on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Barclays raised their price target on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a research report on Tuesday, January 28th. Wells Fargo & Company lowered their price objective on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 23rd. Bank of America reduced their target price on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a report on Thursday, January 23rd. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, February 19th. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average target price of $170.67.

Johnson & Johnson Trading Up 0.4 %

Johnson & Johnson stock opened at $163.69 on Friday. The business has a 50-day simple moving average of $150.48 and a two-hundred day simple moving average of $156.02. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $168.85. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The company has a market cap of $394.11 billion, a P/E ratio of 24.62, a P/E/G ratio of 2.56 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm’s revenue was up 5.3% on a year-over-year basis. During the same period in the prior year, the company earned $2.29 earnings per share. Analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.03%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the transaction, the executive vice president now directly owns 15,098 shares in the company, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Mark A. Weinberger bought 1,000 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, December 12th. The stock was purchased at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the acquisition, the director now directly owns 1,000 shares in the company, valued at $147,220. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.